VXRT

Vaxart Presentation at World Vaccine Congress: Vaxart, Inc. will have Dr. Sean Tucker and Dr. James F. Cummings present their research on oral vaccines at the World Vaccine Congress in Washington, D.C. on April 23, 2025.

About Vaxart's Vaccine Development: Vaxart is a biotechnology company focused on developing oral recombinant vaccines that can be stored without refrigeration, targeting diseases like coronavirus, norovirus, and influenza, while also working on a therapeutic HPV vaccine.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Earnings Reports Today: Major companies such as FedEx, Nike, and Micron are set to report earnings today, with expected stock price movements indicated by options prices.

Options Trading Insights: Investors can view the implied moves for each company based on their earnings release timing, but should conduct thorough research due to the risks associated with options trading.

Major Earnings Reports: Key companies reporting earnings after the market close on Thursday include Micron Technology, NIKE, FedEx Corporation, Luminar Technologies, and Ouster.

Additional Earnings Releases: Other companies expected to release their earnings include CIG, HTHT, IDN, LEN, MGNX, PL, QUBT, RKDA, RWAY, SKYE, and VXRT.

Earnings Announcement: Vaxart (NASDAQ: VXRT) will release its FY earnings results on March 20th, with an expected EPS of -$0.40 and revenue of $34.3M, reflecting significant year-over-year growth.

Performance History: Over the past two years, Vaxart has successfully beaten EPS and revenue estimates 63% of the time.

Phase 1 Clinical Trial Announcement: Vaxart, Inc. has initiated a Phase 1 clinical trial for its second-generation oral norovirus vaccine, aiming to demonstrate improved immune responses compared to its first-generation constructs, with topline data expected by mid-2025.

Future Development Plans: If the Phase 1 trial is successful, Vaxart plans to conduct a Phase 2 safety and immunogenicity study in late 2025, potentially leading to a Phase 3 trial as early as 2026, while emphasizing the urgent need for norovirus vaccines amid rising cases.

Vaxart's Norovirus Vaccine Trial Results: Vaxart, Inc. announced positive results from its Phase 1b trial of an oral norovirus vaccine for elderly adults, showing strong antibody responses and safety, which may be particularly beneficial for older individuals who typically have weaker immune responses to traditional vaccines.

Future Developments in Vaccine Research: The company plans to initiate a Phase 1 clinical trial for a second-generation oral norovirus vaccine in early 2025, building on the promising findings of the first-generation candidate that demonstrated effective immunogenicity and safety in older populations.

Kennedy's Leadership Changes: Robert F. Kennedy Jr. is initiating changes in how the federal government manages vaccine oversight as he begins his role in the Health and Human Services Department.

Scrutiny of Vaccine Processes: Under Kennedy's leadership, there has been a cancellation of meetings with infectious-disease experts and an increased examination of vaccine contracts.

Biotechnology Market Performance: Biotechnology shares are underperforming, down approximately 2%, with Vaxart and Invivyd experiencing significant declines of about 27.9% and 22.3%, respectively.

Sector Laggards: The article highlights the poor performance of biotechnology stocks alongside computers as notable laggards in the market on Monday.

Funding and Clinical Trials: Vaxart, Inc. has amended its funding agreement with Advanced Technology International, increasing financial support for its Phase 2b clinical trial of an oral COVID-19 vaccine candidate to approximately $240.1 million, while also securing an additional $4.6 million for the trial.

Leadership Changes and Financial Growth: The company appointed Kevin Finney to its Board of Directors and reported a revenue increase to $4.9 million for Q3 2024, reflecting strategic advancements in its oral vaccine development amidst ongoing efforts to comply with Nasdaq listing requirements.

COVID-19 and Norovirus Trials: Vaxart is preparing to initiate a Phase 2b trial for its oral COVID-19 vaccine with 10,000 participants pending FDA review, while also moving forward with a Phase 1 study for its second-generation norovirus vaccine expected to start in early 2025.

Avian Influenza Vaccine Development: The company is testing a new avian influenza vaccine candidate in preclinical studies and aims to secure funding through partnerships to support its ongoing clinical programs and extend its cash runway into 2026.

Vaxart's Phase 2b Trial Update: Vaxart, Inc. received a positive recommendation from an independent Data Safety Monitoring Board to continue its COVID-19 Phase 2b trial without modifications, which compares its oral vaccine candidate to an approved mRNA vaccine.

Funding and Future Plans: The company is seeking FDA review and BARDA approval for the trial, which aims to enroll around 10,000 participants, supported by a project award valued at up to $460.7 million under Project NextGen.

DSMB Recommendation: An independent Data Safety Monitoring Board has recommended that Vaxart's COVID-19 Phase 2b trial proceed without modifications based on a safety assessment of initial data from 400 participants.

Trial Expansion Plans: Vaxart plans to expand the trial to enroll 10,000 participants pending favorable review from the FDA and approval from BARDA, aiming to compare its oral vaccine candidate with an approved mRNA vaccine.

Biotechnology Sector Performance: Biotechnology shares are showing relative strength, with the sector up approximately 1.6%, driven by gains in Thermo Fisher Scientific (up 2.4%) and Vaxart (up 1.8%).

Market Commentary: The views expressed in the article reflect the author's opinions and do not necessarily align with those of Nasdaq, Inc.

Major Earnings Reports: Key companies reporting earnings after the market close on Wednesday include Cisco Systems, Bionano Genomics, Nu Holdings Ltd., Vaxart, and Canoo.

Additional Earnings Releases: A wide range of other companies are also scheduled to release their earnings reports after Wednesday's close, including ADAP, AEMD, AGRO, and many more.

Vaxart's Upcoming Presentation: Vaxart, Inc. will present its research on COVID-19 and norovirus oral pill vaccine candidates at the World Vaccine Congress Europe 2024 in Barcelona from October 28-31, featuring updates on clinical trials.

Innovative Vaccine Development: The company focuses on developing oral vaccines that are easy to store and administer, aiming to address significant health challenges with a platform that has shown promising immune responses and safety in trials.

Moderna's Financial Outlook: Moderna Inc. announced cost-reduction plans and lowered its revenue guidance for 2025, which is nearly 8% lower than the 2024 forecast, raising concerns among analysts about the company's profitability timeline.

Impact on Investor Confidence: The revised forecasts have led to a series of downgrades from analysts, with indications that investor confidence is waning, negatively affecting the company's stock performance.

Inducement Equity Awards: Vaxart, Inc. granted inducement equity awards totaling 32,250 shares to two new non-executive employees to encourage them to join the company, consisting of stock options and restricted stock units with specific vesting schedules.

Company Overview: Vaxart is a clinical-stage biotechnology firm focused on developing oral recombinant vaccines that can be stored without refrigeration, targeting diseases like coronavirus, norovirus, influenza, and HPV, while holding patents for its innovative delivery technology.

Vaxart's Vaccine Technology: Vaxart, Inc. announced promising pre-clinical data for its mucosal vaccine platform aimed at treating HPV-related cervical dysplasia, showing potential to stimulate immune responses and improve survival rates in mice.

Market Response: Following the announcement, Vaxart's stock price decreased by 2.7 percent, trading at $0.8643 on the Nasdaq.

Analyst Coverage and Price Forecast: Oppenheimer has initiated coverage of Vaxart (NasdaqCM:VXRT) with an Outperform recommendation, projecting a potential price increase of 805.33% from its current price of $0.59/share, with a one-year target average of $5.36/share.

Institutional Ownership Trends: Institutional ownership in Vaxart has increased significantly, with total shares owned rising by 176.80% over the last three months, indicating a bullish sentiment as reflected in the low put/call ratio of 0.12.